Consultant Neurosurgeon, Head of Neuro Oncology Surgery, Program director of fellowship program
King Hussein Cancer Centre
Dr. Mouness Obeidat, MBBS, MRCS, FEBNS, FRCS(SN), serves as the head of oncological neurosurgery and the program director of the neuro-oncology surgery fellowship at King Hussein Cancer Centre (KHCC) in Amman, Jordan.
Dr. Obeidat graduated from the University of Science and Technology in Jordan with a Medical Bachelor’s degree / Bachelor of Surgery (MBBS) in 2007. He subsequently completed higher specialty training in neurosurgery at the University of Science and Technology/King Abdullah University Hospital in 2014.
Dr. Obeidat holds the Jordanian Board of Neurosurgery, the European Board of Neurosurgery (FEBNS), the Membership of the Royal College of Surgeons (England) (MRCS), and the Fellowship of the Royal College of Surgeons (Surgical Neurology) (FRCS(SN)).
He completed three fellowships at the University of Oxford, UK, specializing in Spine, Paediatric Neurosurgery, and Oncological Neurosurgery. Additionally, he received training in Gamma Knife and Lateral Skull Base Surgery from the National Hospital of Neurology and Neurosurgery in London, UK.
Since 2022, Dr. Obeidat has been appointed as a neurosurgery consultant and head of oncological neurosurgery at KHCC.
At KHCC, he manages a highly active practice with approximately 300 neuro-oncology surgery cases annually. He oversees the only neuro-oncology surgery fellowship program in the region and utilizes cutting-edge technologies, including an intraoperative MRI brain suite, a comprehensive endoscopic cranial and transsphenoidal surgery service, an awake craniotomy service, and a full intraoperative neuro monitoring service that includes MEPs, SSEPs, BAER, CN 2-12 monitoring, Internal Urinary Sphincter/Pudendal/ and Phrenic Nerve Monitoring. Furthermore, he has introduced the first integrated BK intraoperative Ultrasound and Laser Interstitial Thermal Therapy (LITT) service in the MENA region.
Disclosure(s): No financial relationships to disclose
Friday, May 1, 2026
3:00 PM - 3:20 PM CT